IT201600116554A1 - Probiotic yeasts as novel vaccination vectors - Google Patents

Probiotic yeasts as novel vaccination vectors

Info

Publication number
IT201600116554A1
IT201600116554A1 IT102016000116554A IT201600116554A IT201600116554A1 IT 201600116554 A1 IT201600116554 A1 IT 201600116554A1 IT 102016000116554 A IT102016000116554 A IT 102016000116554A IT 201600116554 A IT201600116554 A IT 201600116554A IT 201600116554 A1 IT201600116554 A1 IT 201600116554A1
Authority
IT
Italy
Prior art keywords
vaccination vectors
novel vaccination
probiotic yeasts
probiotic
yeasts
Prior art date
Application number
IT102016000116554A
Other languages
Italian (it)
Inventor
Mateus Bruno Goncalo Douradinha
Original Assignee
Fond Ri Med
Univ Of Pittsburgh – Of The Commonwealth System Of Higher Education
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fond Ri Med, Univ Of Pittsburgh – Of The Commonwealth System Of Higher Education filed Critical Fond Ri Med
Priority to IT102016000116554A priority Critical patent/IT201600116554A1/en
Priority to PCT/EP2017/079557 priority patent/WO2018091637A1/en
Publication of IT201600116554A1 publication Critical patent/IT201600116554A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • C07K14/16—HIV-1 ; HIV-2
    • C07K14/162—HIV-1 ; HIV-2 env, e.g. gp160, gp110/120, gp41, V3, peptid T, CD4-Binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/062—Ascomycota
    • A61K36/064—Saccharomycetales, e.g. baker's yeast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • AIDS & HIV (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IT102016000116554A 2016-11-17 2016-11-17 Probiotic yeasts as novel vaccination vectors IT201600116554A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
IT102016000116554A IT201600116554A1 (en) 2016-11-17 2016-11-17 Probiotic yeasts as novel vaccination vectors
PCT/EP2017/079557 WO2018091637A1 (en) 2016-11-17 2017-11-17 Probiotic yeasts as novel vaccination vectors

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT102016000116554A IT201600116554A1 (en) 2016-11-17 2016-11-17 Probiotic yeasts as novel vaccination vectors

Publications (1)

Publication Number Publication Date
IT201600116554A1 true IT201600116554A1 (en) 2018-05-17

Family

ID=58609729

Family Applications (1)

Application Number Title Priority Date Filing Date
IT102016000116554A IT201600116554A1 (en) 2016-11-17 2016-11-17 Probiotic yeasts as novel vaccination vectors

Country Status (2)

Country Link
IT (1) IT201600116554A1 (en)
WO (1) WO2018091637A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021023348A2 (en) * 2019-05-21 2022-02-01 Esperovax Inc Oral yeast vaccination

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0518443A1 (en) * 1984-10-31 1992-12-16 Chiron Corporation Recombinant proteins of viruses associated with lymphadenopathy syndrome and/or acquired immune deficiency syndrome
WO2001092470A2 (en) * 2000-03-02 2001-12-06 Emory University Dna expression vectors and methods of use

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004058157A2 (en) 2002-12-16 2004-07-15 Globeimmune, Inc. Yeast-based vaccines as immunotherapy

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0518443A1 (en) * 1984-10-31 1992-12-16 Chiron Corporation Recombinant proteins of viruses associated with lymphadenopathy syndrome and/or acquired immune deficiency syndrome
WO2001092470A2 (en) * 2000-03-02 2001-12-06 Emory University Dna expression vectors and methods of use

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
H ZHANG ET AL.: "Antibodies elicited by yeast glycoproteins recognize HIV-1 virions and potently neutralize virions with high mannose N-glycans", VACCINE, vol. 39, no. 33, 13 August 2015 (2015-08-13), ELSEVIER, pages 5140 - 5147, XP029272457, ISSN: 0264-410X *
L H NAGY ET AL.: "Chronic HIV infection enhances the responsiveness of antigen presenting cells to commensal Lactobacillus", PLOS ONE, vol. 8, no. 8, E72789, August 2013 (2013-08-01), Public Library of Science, pages 1 - 12, XP002772797, ISSN: 1932-6203 *
V CHAMCHA ET AL.: "Oral immunization with a recombinant Lactococcus lactis - expressing HIV-1 antigen on group A streptococcus pilus induces strong mucosal immunity in the gut", THE JOURNAL OF IMMUNOLOGY, vol. 195, 19 October 2015 (2015-10-19), The American Association of Immunologists, pages 5025 - 5034, XP021116244, ISSN: 0022-1767 *

Also Published As

Publication number Publication date
WO2018091637A1 (en) 2018-05-24

Similar Documents

Publication Publication Date Title
HK1244034A1 (en) Tri-segmented arenaviruses as vaccine vectors
DK3393510T5 (en) ZIKAVIRUS VACCINE
MA42543A (en) CONCATEMERIC PEPTIDIC EPITOPE RNA
DK3194567T3 (en) Probiotic Bifidobacterium adolescentis strains
PT3207053T (en) Novel immunogenic peptides
DK3253402T3 (en) Recombinant probiotic bacteria
DK3247791T3 (en) UNIVERSAL KILLER T CELL
DK3157559T3 (en) ANTI-AXL ANTIBODIES
CL2016001742A1 (en) Novel anti-baff antibodies
CL2016002146A1 (en) Immunostimulatory plasmids
DK3129007T3 (en) Vaccine compositions
DK3228312T3 (en) IMMUNE REGULATOR
DK3113795T3 (en) RECOMBINANT VIRAL ISFAHAN VECTORS
GB201608197D0 (en) Novel proteins
DK3201222T3 (en) Recombinant mutants
IL247535B (en) Poxviral oncolytic vectors
EP3423090C0 (en) Novel influenza antigens
DK3198017T3 (en) VIRUS-BASED EXPRESSION VECTORS AND USES THEREOF
IT201600116554A1 (en) Probiotic yeasts as novel vaccination vectors
GB201603963D0 (en) Whole cell vaccine
DK3197487T3 (en) VACCINATION OF IMMUNE COMPROMISED INDIVIDUALS
TH1501004685A (en) Eyelash cosmetics
TH1501006124A (en) fermented soy milk
TH1601003632A (en) Lactobacillus salivarius for the treatment of mastitis
TH1601003238A (en) Swine vaccine